Seek Labs wins U.S. patent

Molecular diagnostics are great at finding tiny amounts of viral or bacterial genetic material. The problem is that the best-known version — PCR — usually wants a machine, controlled temperatures, and a real lab. That is exactly what breaks down in clinics, field settings, and low-infrastructure testing programs. Seek Labs says it just locked up a key piece of that bottleneck with a new U.S. patent issued on May 7. (businesswire.com) ### What did Seek Labs actually get? The company said the USPTO issued U.S. Patent No. 12,618,795 B2. The patent covers something Seek Labs calls ANINA — short for Asymmetric Semi-Nested Isothermal Nucleotide Amplification — which it describes as a core assay-design element inside its Seek Amplification platform. (busine([businesswire.com)y is “isothermal” the important word? PCR works by heating and cooling a sample over and over to copy nucleic acid. Isothermal amplification tries to do the same basic job at one temperature. That sounds like a small engineering tweak, but it is the whole game for portable diagnostics — fewer heaters, less power draw, less instrumentation, and a better shot at running outside a central lab. (business.sherbrookerecord.com) ### What is Seek Labs claiming its version fixes? Seek Labs is not just saying “we also do isothermal.” The company’s materials frame Seek Amplification as chemistry designed to reduce temperature and instrumentation constraints while staying sensitive enough for molecular detection. On i(business.sherbrookerecord.com)tprint. (business.sherbrookerecord.com) ### Why does a patent matter here? Because in diagnostics, the chemistry is often the product. A point-of-care test can look simple on the outside, but the moat often sits in the reagents, primer design, and workflow steps that make the assay actually work in messy real-world samples. If (business.sherbrookerecord.com)ommercial logic of this kind of IP. (business.sherbrookerecord.com) ### Is this a full product approval? No — and that distinction matters. A U.S. patent means the government granted exclusion rights over a claimed invention. It does not mean the FDA cleared a test, hospitals adopted it, or buyers validated performance at scale. The patent is about ownership and defensibility, not clinical-market traction by itself. (businesswire.com) ### Where is Seek Labs trying to use this? The company says the patent supports applications in respiratory and other infectious-disease diagnostics. Other Seek Labs materials point to tuberculosis and broader field-deployable molecular testing as target use cases, which fits the company’s larger pitch around decentralized diagnosis in places where power, instrumentation, and trained staff are limited. (business.sherbrookerecord.com) ### What should readers watch next? Two things. First, whether Seek Labs turns this IP into named partnerships, assay launches, or procurement wins. Second, whether the company can show performance data that proves the chemistry works reliably outside controlled lab settings. Patents can open doors — but diagnostics companies only really win when the workflow is cheap, rugged, and trusted. (businesswire.com) ### Bottom line? Seek Labs did not just announce vague “innovation.” It got a specific U.S. patent on a core amplification method meant to make molecular testing work with less equipment and less infrastructure. If that chemistry performs the way the company says, the patent could become a real asset in decentralized infectious-disease testing. (businesswire.com)